New Delhi: Global pharma and biotech company Wockhardt on Thursday received approval from Drugs Controller General of India (DCGI) for its two new antibiotic, EMROK (IV) and EMROK O (Oral), it said in a regulatory filing.
EMROK (IV) and EMROK (Oral) will help treat acute bacterial skin and skin structure infections including diabetic foot infections and concurrent bacteraemia. It is a multi-spectrum methicillin-resistant staphylococcus aureus (MRSA) drug. MRSA is responsible for several difficult-to-treat infections in humans.
Currently, available anti-MRSA agents have multiple side effects such as kidney damage, decrease in platelet cell counts and muscle pain, Wockhardt claimed. The new anti-MRSA agent will be made available after a gap of 14 years, it added.
“By virtue of its broad spectrum activity against widely prevalent pathogens including MRSA, superior safety over the currently available anti-MRSA agents and its unique properties, I believe EMROK/EMROK-O has a strong potential to effectively address the unmet medical need of the clinicians in the country thereby helping to reduce the morbidity and mortality,” said Dr. Habil Khorakiwala, founder chairman, Wockhardt Group.
India carries one of the largest burdens of drug-resistant pathogens worldwide. Infections caused by drug-resistant organisms could lead to increased mortality and prolonged duration of hospitalization.
According to the IQVIA data, the Indian antibiotic market is pegged at ₹16,000 crore. Growing at 7%, it is one of the largest therapeutic segments, with a 12% market share of the Indian pharmaceutical market, according to the statement.